Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab and chemotherapy vs bevacizumab and chemotherapy in recurrent ovarian cancer
2017-000202-37Phase 3Completed
- Sponsor
- AGO Research
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of atezolizumab in ovarian cancer (OC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by AGO Research. Primary endpoint: Overall Survival. Started Dec 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancer (OC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2017-000202-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000202-37.